Drug
Ampreloxetine clinical trials
Also written TD-9855.
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ampreloxetine is read from its arms, and is right about nine times in ten.
Testing it · 10
- Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System AtrophyActive, not recruitingPhase 3Theravance BiopharmaNCT05696717Written as Ampreloxetine
- Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureTerminatedPhase 3Theravance BiopharmaNCT03829657Written as ampreloxetine
- Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureTerminatedPhase 3Theravance BiopharmaNCT04095793Written as ampreloxetine
- TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)CompletedPhase 2Theravance BiopharmaNCT02705755Written as TD-9855
- Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureCompletedPhase 3Theravance BiopharmaNCT03750552Written as ampreloxetine
- A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedPhase 2Theravance BiopharmaNCT01458340Written as TD-9855
- Phase 2 Study of TD-9855 to Treat FibromyalgiaCompletedPhase 2Theravance BiopharmaNCT01693692Written as TD-9855 Group 1
- Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855CompletedPhase 1Theravance BiopharmaNCT04200573Written as Ampreloxetine
- TD-9855 Mass Balance StudyCompletedPhase 1Theravance BiopharmaNCT01924143Written as TD-9855
- Drug-Drug Interaction (DDI) Study for TD-9855CompletedPhase 1Theravance BiopharmaNCT03432793Written as TD-9855
Codes
What other systems call ampreloxetine · ClinicalTrials.gg INT000322
- MeSH (NLM) C000601820ampreloxetineOne source NLM
- UNII (FDA) 19997EZ42IAMPRELOXETINEConfirmed FDA, NLM, Wikidata
- Wikidata Q130478613ampreloxetineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166483AmpreloxetineOne source FDA
- DrugBank DB15348One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000601820 | ampreloxetine | One source NLM |
| UNII (FDA) | 19997EZ42I | AMPRELOXETINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q130478613 | ampreloxetine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166483 | Ampreloxetine | One source FDA |
| DrugBank | DB15348 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.